There have been limited studies for patients with chronic liver disease (CLD), including cirrhosis, Hep B, Hep C and chronic non alcoholic liver disease, in determining the risk associated with COVID-19. Further effects of age, race and gender have also not been studied as it pertains to CLD. What is known, however is that the coronavirus can damage the liver and higher mortality rates have been associated with CLD. Furthermore, people with CLD often have abnormal immune function, systemic inflammation, and/or other COVID-19 comorbidities causing an overlap of risk factors.